Sheaff Brock Investment Advisors LLC Increases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Sheaff Brock Investment Advisors LLC raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 13.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,238 shares of the company’s stock after purchasing an additional 268 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Neurocrine Biosciences were worth $258,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. ProShare Advisors LLC raised its stake in shares of Neurocrine Biosciences by 3.3% in the first quarter. ProShare Advisors LLC now owns 11,829 shares of the company’s stock worth $1,631,000 after purchasing an additional 383 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Neurocrine Biosciences by 34.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,194 shares of the company’s stock valued at $7,612,000 after acquiring an additional 14,015 shares during the period. Blair William & Co. IL boosted its holdings in shares of Neurocrine Biosciences by 5.9% during the 1st quarter. Blair William & Co. IL now owns 8,599 shares of the company’s stock valued at $1,186,000 after acquiring an additional 481 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Neurocrine Biosciences by 97.2% in the first quarter. Intech Investment Management LLC now owns 24,186 shares of the company’s stock worth $3,336,000 after acquiring an additional 11,921 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Neurocrine Biosciences by 2.3% during the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after purchasing an additional 220,598 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Down 4.4 %

NASDAQ:NBIX opened at $117.44 on Friday. The business’s 50-day moving average is $118.50 and its 200 day moving average is $132.66. Neurocrine Biosciences, Inc. has a 12 month low of $107.84 and a 12 month high of $157.98. The company has a market capitalization of $11.89 billion, a P/E ratio of 31.49 and a beta of 0.35.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on NBIX shares. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 1st. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Royal Bank of Canada reduced their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Finally, Jefferies Financial Group increased their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.